ICD and Pacemaker Implantation: The Device Decision and What the First Year Looks Like

The Scene

The following scene is drawn from the composite of patients I have cared for in clinic and on the hospital floor. All identifying details are changed.

He was sixty-three years old, with an ejection fraction of 28 percent, ischemic cardiomyopathy, LBBB on his ECG, and New York Heart Association Class II symptoms on improved guideline-directed medical therapy that had been in place for fourteen months. His clinical picture met guideline criteria for both a cardiac resynchronization therapy defibrillator (CRT-D) and a primary prevention ICD. The electrophysiologist met with him for forty-five minutes.

He came out of that meeting knowing more about the device specifications than he needed to know and considerably less about what the first year of living with an ICD would actually be like. He did not know that the device would not change how he felt on a day-to-day basis. He did not know that an appropriate ICD shock, if he ever received one, would feel like a blow to the chest from the inside. He did not know that the device records every cardiac event and transmits data nightly to a monitoring system. He did not know that the first 30 days post-implant carried the highest infection and hematoma risk and that the driving restriction applied to him.

He also did not know that the ICD would only fire if his heart went into a life-threatening ventricular arrhythmia, and that most ICD patients go years or decades without ever receiving a shock. The device is not a continuous intervention. It is a standby rescue.

The cardiac electrophysiology program at Carle Foundation Hospital in Urbana-Champaign performs pacemaker and ICD implantation with dedicated device follow-up clinics and remote monitoring integration. The range of devices implanted spans from simple single-chamber pacemakers to complex subcutaneous ICDs and leadless pacemakers.

What It Is

Pacemaker: A cardiac implanted electronic device (CIED) consisting of a pulse generator (battery and circuitry) and one or more leads that deliver electrical impulses to the heart to maintain an adequate heart rate and rhythm. Pacemakers do not treat life-threatening arrhythmias. They prevent symptomatic bradycardia (heart rate too slow).

Implantable cardioverter-defibrillator (ICD): A device that combines pacemaker capability with the ability to detect and terminate ventricular tachycardia (VT) and ventricular fibrillation (VF) through antitachycardia pacing (ATP) and high-energy shock delivery. ICDs are implanted for primary prevention of sudden cardiac death (in patients with high arrhythmic risk but no prior life-threatening arrhythmia) or secondary prevention (in patients who have survived a life-threatening arrhythmia).

CRT (Cardiac Resynchronization Therapy): Biventricular pacing that coordinates left and right ventricular contractions to improve cardiac output in patients with heart failure and wide QRS, particularly LBBB. CRT can be delivered via a CRT-P (pacemaker only) or CRT-D (pacemaker plus defibrillator). The CRT-D combines resynchronization with arrhythmia protection.

Subcutaneous ICD (S-ICD): An ICD with no transvenous leads. The generator sits subcutaneously in the left lateral chest wall. The sensing lead runs subcutaneously along the sternum. S-ICD can detect VF and deliver a 80-joule shock but cannot provide anti-tachycardia pacing, bradycardia pacing, or CRT. Appropriate for patients who need defibrillation protection without pacing requirements.

Leadless pacemaker (e.g., Micra AV): A capsule-sized pacemaker deployed via femoral vein catheter and anchored in the right ventricle without any subcutaneous pocket or transvenous lead. Approved for single or dual-chamber pacing. Substantially lower infection and lead complication rates than conventional transvenous systems 5 / Solid .

The Mechanism

Pacemaker sensing and pacing: The device continuously monitors the intracardiac electrogram from its leads. When it detects intrinsic cardiac activity (patient’s own P waves or R waves) above a programmed rate, it inhibits pacing. When it detects no activity for a programmed interval, it delivers a small electrical impulse (typically 0.5 to 2.5 volts at 0.4 to 0.5 ms pulse width) to the adjacent myocardium, initiating depolarization and contraction. Modern devices use demand pacing: they pace only when needed, minimizing unnecessary stimulation and extending battery life.

ICD arrhythmia detection and therapy: The ICD continuously analyzes the ventricular electrogram rate and morphology. Detection zones are programmed at implant:

• VT zone (typically 150 to 200 bpm): The device first attempts ATP, a series of pacing impulses faster than the VT rate designed to interrupt the re-entrant circuit without a shock. ATP terminates monomorphic VT in 85 to 90 percent of cases without the patient feeling any intervention.
• VF zone (typically greater than 200 bpm): The device charges its capacitor (1 to 4 seconds) and delivers a high-energy shock (10 to 35 joules for transvenous ICDs, 80 joules for S-ICDs). This is felt as an intense sudden blow.

Lead positioning: For a standard dual-chamber pacemaker or ICD, two leads are placed transvenously via the subclavian or axillary vein: a right ventricular lead (positioned at the right ventricular apex or high septal position) and a right atrial lead (positioned at the right atrial appendage). For CRT, a third lead is placed via the coronary sinus into a lateral branch of the left ventricle, positioning the tip adjacent to the posterior or lateral left ventricular free wall. This LV lead placement is the most technically challenging step in CRT implantation and takes the most fluoroscopy time.

The implant suite: Device implantation is performed in a cardiac catheterization laboratory, electrophysiology laboratory, or hybrid OR under fluoroscopic guidance. Patients receive local anesthesia with sedation (rarely general anesthesia). The procedure takes 45 minutes to 3 hours depending on device complexity. Real-time fluoroscopy guides lead navigation through the venous system and into the cardiac chambers. Electrogram measurements confirm adequate lead placement (sensing amplitude, pacing threshold, impedance). The lead is actively fixed (helix tip screwed into myocardium) or passively anchored (tines embedding into trabecular muscle).

Pocket creation: The pulse generator sits in a subcutaneous pocket created below the left clavicle, typically between the pectoral fascia and the pectoralis major muscle (prepectoral) or, in thinner patients, deeper (subpectoral or below the fascia). Pocket position affects comfort, cosmetic appearance, and infection risk. The wound is closed in layers. Total procedure closure takes 15 to 30 minutes.

How It Is Used

Pacemaker indications: The primary indications are symptomatic bradycardia from sinus node dysfunction or atrioventricular conduction disease.

Sinus node dysfunction: Sinus bradycardia with symptoms (fatigue, syncope, exercise intolerance), sinus pauses causing presyncope or syncope, chronotropic incompetence (failure to increase heart rate with exercise). Permanent pacemaker is indicated when a correctable reversible cause (drug effect, hypothyroidism, hypothermia) has been excluded 5 / Solid .

AV conduction disease: High-degree AV block (second-degree Mobitz II, third-degree/complete heart block) with or without symptoms. Complete heart block with a junctional escape rhythm below 40 bpm is a Class I indication even without symptoms.

Post-ablation AV block: Iatrogenic complete heart block following AV nodal ablation or TAVR procedure requires permanent pacing.

ICD indications: ICD implantation is divided into primary and secondary prevention.

Primary prevention: Prophylactic ICD in patients at high risk for sudden cardiac death who have not yet had a life-threatening arrhythmia. The primary indication is ischemic or non-ischemic cardiomyopathy with LVEF 35 percent or less, NYHA class II or III symptoms, on guideline-directed medical therapy for at least 3 months 5 / Solid . Additional primary prevention indications include hypertrophic cardiomyopathy with high-risk features, ARVC, Brugada syndrome after cardiac arrest or with high-risk features, and long QT syndrome with high-risk features.

Secondary prevention: ICD after survival from VF, sustained hemodynamically unstable VT, or VT causing syncope, in the absence of a reversible cause. The AVID trial established secondary prevention ICD superiority over antiarrhythmic drug therapy 5 / Solid Investigators, N Engl J Med. 1997; doi:10.1056/NEJM199710023371402).

CRT indications: CRT is indicated for symptomatic heart failure (NYHA II-IV), LVEF 35 percent or less, QRS duration 150 ms or greater with LBBB morphology, on guideline-directed medical therapy. The evidence base is strongest for LBBB with QRS 150 ms or greater. Non-LBBB with QRS 150 ms has weaker evidence 5 / Solid .

The Evidence

SCD-HeFT: Primary Prevention ICD in Heart Failure

The SCD-HeFT trial (Sudden Cardiac Death in Heart Failure Trial) enrolled 2,521 patients with NYHA class II or III heart failure and LVEF 35 percent or less (both ischemic and non-ischemic cardiomyopathy) and randomized them to ICD, amiodarone, or placebo 5 / Solid .

Results:

• ICD vs placebo: HR for all-cause mortality 0.77 (95% CI 0.62 to 0.96; p = 0.007)
• Absolute risk reduction: 7.2 percent over 45 months
• Amiodarone vs placebo: no significant survival benefit

SCD-HeFT established the class I indication for primary prevention ICD in both ischemic and non-ischemic cardiomyopathy with EF 35 percent or less. It is the foundational trial for the current ICD guideline framework.

MADIT-II: ICD After MI With Low EF

MADIT-II enrolled 1,232 patients with prior MI and LVEF 30 percent or less and randomized them to ICD vs medical therapy. The trial was stopped early due to clear benefit 5 / Solid .

Results:

• All-cause mortality: 14.2 percent (ICD) vs 19.8 percent (medical therapy)
• Hazard ratio: 0.69 (95% CI 0.51 to 0.93; p = 0.016)

This trial extended the ICD indication to patients with prior MI and low EF without requiring inducible arrhythmia on EP study, which had been the prior standard.

DANISH Trial: Non-Ischemic Cardiomyopathy

The DANISH trial enrolled 1,116 patients with non-ischemic cardiomyopathy and symptomatic heart failure (LVEF 35 percent or less) and randomized them to ICD or standard therapy 5 / Solid .

Results:

• All-cause mortality: 21.6 percent (ICD) vs 23.4 percent (standard therapy)
• Hazard ratio: 0.87 (95% CI 0.68 to 1.12; p = 0.28), not significant
• Subgroup analysis: trend toward ICD benefit in patients under age 68

DANISH cast doubt on the benefit of prophylactic ICD in non-ischemic cardiomyopathy in the era of cardiac resynchronization therapy and modern heart failure management, where competing risks (heart failure death, non-cardiac death) may dilute the arrhythmia-specific benefit of ICD. This trial is why the guidelines continue to give a class I indication but clinical discussions with individual patients, particularly older patients with non-ischemic cardiomyopathy, have become more nuanced.

WRAP-IT Trial: Antibiotic Envelope for Infection Prevention

The WRAP-IT trial enrolled 6,983 patients undergoing CIED implantation or pocket revision and randomized them to an absorbable antibacterial envelope (TYRX) impregnated with minocycline and rifampin versus standard care 5 / Solid .

Results:

• Major CIED infection at 12 months: 0.7 percent (envelope) vs 1.2 percent (control)
• Hazard ratio: 0.60 (95% CI 0.36 to 0.98; p = 0.04)
• Absolute risk reduction: 0.5 percent
• Number needed to treat: 200 patients to prevent one major infection

WRAP-IT established the antibiotic envelope as a Class IIa recommendation for reducing CIED infection in patients undergoing device upgrade, generator replacement, or initial implantation with significant infection risk factors (diabetes, renal insufficiency, corticosteroid use, prior generator manipulation). The absolute risk reduction is modest, but CIED infections carry substantial morbidity (device extraction, prolonged hospitalization, bacteremia) and the procedure to deploy the envelope adds minimal time and risk.

CARE-HF: CRT in Heart Failure

The CARE-HF trial enrolled 813 patients with NYHA III-IV heart failure, LVEF 35 percent or less, and QRS 120 ms or greater and randomized them to CRT-P versus medical therapy 5 / Solid .

Results:

• All-cause mortality or hospitalization for cardiovascular event: 39 percent (CRT) vs 55 percent (medical therapy); HR 0.63; p less than 0.001
• All-cause mortality: HR 0.64 (95% CI 0.48 to 0.85; p = 0.002)

CRT reduced both symptoms (NYHA class, quality of life, six-minute walk distance) and mortality in appropriately selected patients. The benefits were most pronounced in patients with LBBB morphology. CRT remains the most effective device therapy for symptoms and survival in heart failure with dyssynchrony.

Post-Implant Infection Risk

CIED infection incidence is approximately 1 to 2 percent per procedure. Risk factors include diabetes, renal insufficiency, prior device infection, corticosteroid use, operator experience, and early pocket hematoma requiring re-exploration. CIED infection requiring device extraction has an in-hospital mortality of 5 to 7 percent 5 / Solid . Prevention strategies include MRSA nasal decolonization, IV antibiotics (typically cefazolin 1 g IV) 30 to 60 minutes before incision, and the antibiotic envelope for high-risk implants.

The Patient Experience

Pre-Procedure Workup

The pre-implant workup includes current echocardiogram to confirm EF (for ICD indications) or assess lead positioning requirements; assessment of venous access via subclavian vein (ultrasound or venography in complex cases); current medications review with anticoagulation management plan; INR check if on warfarin; creatinine for contrast consideration; and surgical site decolonization protocol (chlorhexidine washes, possibly nasal mupirocin for MRSA carriers).

Anticoagulation management: For most pacemaker and ICD implants, warfarin is NOT interrupted. Continuing warfarin at therapeutic INR (target 2.0 to 3.0) reduces pocket hematoma risk compared with bridging with heparin or LMWH, which causes substantially more hematoma 5 / Solid . DOACs are typically held for 24 to 48 hours before implantation.

The Implant Day

The patient arrives fasting, changes into a gown, and IV access is established. The left chest and axilla are shaved and prepped. Sedation is titrated to patient comfort; most patients are awake but relaxed, often able to respond to questions during the procedure.

The subclavian or axillary vein is accessed via venous puncture. A guidewire is introduced, a sheath placed, and the lead is advanced under fluoroscopic guidance through the right atrium and into the right ventricle (for the ventricular lead) or left secured at the right atrial appendage (for the atrial lead). Fluoroscopy displays the lead as a bright white thread moving through the cardiac chambers in real time. Lead position is confirmed both visually and by electrogram measurements on a programmer.

The pocket is created in the left prepectoral region through a 5 to 7 cm incision below the clavicle. The generator is connected to the leads, tested (defibrillation testing is no longer routine for most ICDs), and placed in the pocket. The wound is closed in layers and a sterile dressing applied. Total procedure time: 45 minutes for a simple pacemaker to 2.5 to 3 hours for a CRT-D in a complex chest anatomy.

What Your Cardiologist Will Not Have Time to Explain

• The arm restriction (no lifting above shoulder on the implant side for 4 to 6 weeks) is not arbitrary. It is to prevent lead dislodgement during the period before fibrosis secures the lead at the implant site.
• Driving restrictions typically last 4 to 6 weeks post-implant for pacemakers, and in most US states, a physician must certify that a patient with an ICD does not have recurrent arrhythmia before resuming driving. If you rely on driving professionally, ask specifically about this before the implant date.
• The device interrogation at each follow-up visit reads a complete log of every cardiac event the device detected since the last visit. This is not a brief checkup; it is a complete arrhythmia review. Bring questions about any episodes of unusual symptoms you had between visits.
• Remote monitoring (via a bedside transmitter that uploads nightly) does not mean continuous human surveillance. It means the data is transmitted and reviewed by a nurse or physician during business hours, or flagged by automated alerts for pre-defined criteria.

Pocket Hematoma

Pocket hematoma is the most common complication of device implantation, occurring in 2 to 4 percent of cases. Risk is substantially higher when anticoagulation is continued with heparin bridging. A hematoma that is enlarging, tense, or associated with skin breakdown requires surgical re-exploration; a small, stable hematoma can often be managed conservatively. Pocket hematoma that requires re-exploration doubles the infection risk.

Sex Differences

Women referred for ICD implantation are more likely to have non-ischemic cardiomyopathy and a higher absolute EF at the time of implant than men, yet receive fewer primary prevention ICD implants relative to their guideline-eligible population 5 / Solid . Women have smaller venous anatomy and smaller cardiac chamber dimensions, affecting lead sizing and positioning. The subcutaneous ICD, which does not require transvenous lead placement, may be particularly well-suited to younger women with primary prevention indications who prefer to avoid long-term transvenous leads. Women are also more likely to experience generator protrusion-related discomfort from the prepectoral pocket in patients with low BMI, and subpectoral pocket placement is considered more frequently.

Geographic Access in Illinois

Permanent pacemaker and ICD implantation services are available at Carle Foundation Hospital in Urbana-Champaign with an electrophysiology-trained team and device clinic follow-up. Complex device implantation including CRT-D, S-ICD, leadless pacemakers, and high-risk patients requiring general anesthesia or concomitant cardiac surgery is available at Northwestern Medicine Bluhm Cardiovascular Institute in Chicago, Rush University Medical Center, and University of Illinois Health, all of which maintain high-volume device programs with complete extraction capability if needed.

Decisions and Trade-Offs

Transvenous ICD Versus Subcutaneous ICD

The choice between a transvenous ICD (TV-ICD) and subcutaneous ICD (S-ICD) depends on whether the patient has a pacing requirement.

S-ICD is appropriate when:

• The patient needs defibrillation protection but has no pacing indication
• The patient is young (30s to 50s) with decades of device life ahead and the priority is to avoid long-term transvenous leads that may require extraction
• Venous access is limited
• Prior transvenous lead infection makes a new transvenous system undesirable

S-ICD is NOT appropriate when:

• Antitachycardia pacing for VT termination is needed (transvenous ICD ATP terminates most VT without shock; S-ICD cannot)
• Bradycardia pacing is needed
• CRT is required

The PRAETORIAN trial randomized 849 patients to S-ICD versus TV-ICD and showed non-inferiority for the combined endpoint of inappropriate shocks and device-related complications over 4 years 5 / Solid . S-ICD had fewer device-related complications (no lead-related issues) but higher rates of inappropriate shocks (6.4 percent vs 9.7 percent at 4 years in TV-ICD vs S-ICD respectively in the original paper; programmability improvements have reduced this).

The Decision to Implant in Non-Ischemic Cardiomyopathy

The DANISH trial’s neutral result in non-ischemic cardiomyopathy has made the ICD discussion more individualized for this population. The clinical variables that shift the risk-benefit calculation toward ICD:

• Patient age below 68 (subgroup with trend toward benefit in DANISH)
• Presence of mid-wall LGE on cardiac MRI (independently associated with arrhythmic risk regardless of EF)
• NSVT on ambulatory monitoring
• Inducible sustained VT on EP study
• Primary prevention despite guideline-directed medical therapy showing no EF improvement

Variables that shift toward no ICD:

• Age above 70 with multiple comorbidities where non-arrhythmic mortality dominates
• No LGE on CMR
• Very recent diagnosis with expected EF recovery on medical therapy (3-month window per guidelines)

The Three Questions Every Patient Should Ask

1. “Is my ejection fraction going to improve enough on medications that I might not need this device?” For newly diagnosed cardiomyopathy, guidelines require 3 to 6 months of guideline-directed medical therapy before ICD implantation (except in secondary prevention or very high-risk patients). An EF that recovers to above 35 percent on medical therapy changes the indication. If your EF was recently measured and you have not been on maximally tolerated medications for at least three months, the implant may be premature.

2. “What happens if my ICD fires?” An appropriate shock terminates a life-threatening arrhythmia. It is effective, painful, and frightening. Post-shock management includes: immediate medical evaluation, electrogram review to confirm appropriate therapy, electrolyte check, thyroid function, medication review, and consideration of ablation if shocks are recurrent. A single appropriate shock in a patient who is well does not necessarily require hospitalization. A patient who received a shock and is hemodynamically compromised needs emergency evaluation.

3. “What is the plan if I decide I do not want device therapy anymore?” ICD deactivation is an ethically and legally appropriate choice in patients who no longer wish to receive resuscitative therapy, including those with terminal illness, advanced dementia, or change in goals of care. This conversation should happen before clinical deterioration forces it. Deactivation is performed non-invasively by a programmer and does not require device removal. Every patient with an ICD should be aware that this option exists and is their right to invoke.

Clinical Synthesis

ICD and pacemaker implantation decisions sit at the intersection of prognosis, quality of life, and patient values. The device either prevents death from arrhythmia or it does not fire because death comes from another cause. The distinction matters for decision-making. An ICD in an 80-year-old with severe heart failure and progressive renal insufficiency may fire appropriately multiple times at end of life, prolonging dying rather than extending meaningful life. An ICD in a 55-year-old with ischemic cardiomyopathy and EF of 28 percent offers a clear survival benefit demonstrated in multiple RCTs.

A structured cardiovascular assessment for a patient with heart failure and low EF includes a structured assessment of whether ICD implantation has been discussed, whether the three-month guideline-directed medical therapy window has been completed, and whether cardiac MRI has been obtained to assess scar burden and refine arrhythmic risk. In patients where the EF is borderline (30 to 40 percent) and the ICD indication is not categorical, the audit identifies whether the decision has been individualized or simply defaulted to guideline minimum.

For patients with pacemakers, the cardiovascular workup assesses whether the device is providing appropriate therapy or contributing to problems. Pacemaker-mediated right ventricular pacing is associated with adverse cardiac remodeling over time and may contribute to heart failure development in patients with normal or mildly reduced EF. His bundle pacing and left bundle branch area pacing, which produce more physiological activation, are increasingly available and may be preferable to RV apical pacing in patients with anticipated high pacing burden 4 / Promising .

Patients considering ICD implantation in central Illinois can be evaluated at Carle Foundation Hospital in Urbana-Champaign, where the electrophysiology program offers device consultation with CMR integration and pre-implant risk stratification. Patients requiring complex device management including lead extraction, upgrade from single-chamber to biventricular devices, or subcutaneous ICD consideration are referred to Northwestern Medicine Bluhm Cardiovascular Institute or Rush University Medical Center, where high-volume EP programs manage the full spectrum of device complexity.

Paired Foundations Articles:

• PROC-008: EP Study (arrhythmia risk stratification before ICD implantation decision)
• PROC-012: Cardiac MRI (LGE-based arrhythmic risk assessment for ICD decisions)
• PROC-007: Cardiac Ablation (VT ablation to reduce ICD shocks)
• PROC-014: Tilt-Table Test (pacemaker for cardioinhibitory vasovagal syncope)

The Signal Check is fifteen questions mapping the cardiovascular risk pattern across the physiological domains most commonly missed in standard screenings. It produces a specific starting point for your next clinical conversation.